FDA Warning No Match For Biden Administration
FDA Releases Statement About Gonadotropin-Releasing Hormone Agonists (GnRH)
The FDA released a statement in July 2022 about gonadotropin-releasing hormone agonists (GnRH) inducing brain swelling, headache, blurred or loss of vision, tinnitus, dizziness, and nausea if injected into children.
FDA Believes Link Between Puberty Blockers and Pseudotumor Cerebri
According to the FDA, six cases were recognized in young girls between 5 to 12 years old with a reasonable link between the puberty blockers and pseudotumor cerebri (increasing pressure inside the skull for no clear reason).
The ailment is also known as idiopathic intracranial hypertension, with symptoms similar to a brain tumor.
Symptoms Started Between Three and 240 Days After Injection
The FDA reported five girls were receiving care for central precocious puberty and one for transgender care.
Symptoms began anywhere from three to 240 days following the girls starting the puberty blockers.
Never miss any important news. Subscribe to our newsletter.
Related News
Never miss any important news. Subscribe to our newsletter.
Recent News
